COVID-19疫苗接种后绝经后出血
该研究在Kaiser Permanente Northwest系统内分析2018至2021年绝经后出血诊断发生率,发现COVID-19疫苗引入前后发生率无统计学显著差异(P=.59);接种后60天内新发绝经后出血104例,其中76%(79/104)经病历复核确认为接种后绝经后出血,中位出血时间21天。
要点
- 疫苗引入前后绝经后出血诊断率无统计学显著差异(P=.59)。
- 接种后60天内新发绝经后出血104例中76%(79/104)确认为接种后绝经后出血。
- 有明确归因的56例中,常见病因为子宫或宫颈病变(50%[28/56])。
核心结论
- 在该整合医疗系统内,COVID-19疫苗引入与绝经后出血新诊断增加无关。
- 接种COVID-19疫苗后60天内诊断绝经后出血罕见。
研究设计与样本
- 采用分段回归分析,月度人群队列为Kaiser Permanente Northwest年龄≥45岁女性成员,纳入电子病历中新诊断绝经后出血者,排除既往绝经后出血或异常子宫出血或因其他健康状况出血风险增高者。
- 每月人群规模为75,530至82,693人。
- 另识别2020年12月14日至2021年8月14日期间接种≥1剂COVID-19疫苗且接种后60天内新诊断绝经后出血的所有成员,通过病历复核评估疫苗接种、诊断操作及推测出血病因。
- 对无明确出血病因的所有病例进行时空扫描统计。
主要发现
- 疫苗引入前后绝经后出血新诊断率无统计学显著差异(P=.59)。
- 接种后60天内新诊断绝经后出血104例,经病历复核76%(79/104)确认为接种后绝经后出血。
- 从接种到出血发生的中位时间为21天(范围:2-54天)。
- 在56例有提供者归因病因的绝经后出血病例中,常见出血原因为子宫或宫颈病变(50%[28/56])、激素替代治疗(13%[7/56])和增殖期子宫内膜(13%[7/56])。
- 在23例无明确病因的病例中,接种后绝经后出血发生时间无统计学显著聚集。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a growing literature base regarding menstrual changes following COVID-19 vaccination among premenopausal people. However, relatively little is known about uterine bleeding in postmenopausal people following COVID-19 vaccination. OBJECTIVE: This study aimed to examine trends in incident postmenopausal bleeding diagnoses over time before and after COVID-19 vaccine introduction, and to describe cases of new-onset postmenopausal bleeding after COVID-19 vaccination. STUDY DESIGN: For postmenopausal bleeding incidence calculations, monthly population-level cohorts consisted of female Kaiser Permanente Northwest members aged ≥45 years. Those diagnosed with incident postmenopausal bleeding in the electronic medical record were included in monthly numerators. Members with preexisting postmenopausal bleeding or abnormal uterine bleeding, or who were at increased risk of bleeding due to other health conditions, were excluded from monthly calculations. We used segmented regression analysis to estimate changes in the incidence of postmenopausal bleeding diagnoses from 2018 through 2021 in Kaiser Permanente Northwest members meeting the inclusion criteria, stratified by COVID-19 vaccination status in 2021. In addition, we identified all members with ≥1 COVID-19 vaccination between December 14, 2020 and August 14, 2021, who had an incident postmenopausal bleeding diagnosis within 60 days of vaccination. COVID-19 vaccination, diagnostic procedures, and presumed bleeding etiology were assessed through chart review and described. A temporal scan statistic was run on all cases without clear bleeding etiology. RESULTS: In a population of 75,530 to 82,693 individuals per month, there was no statistically significant difference in the rate of incident postmenopausal bleeding diagnoses before and after COVID-19 vaccine introduction (P=.59). A total of 104 individuals had incident postmenopausal bleeding diagnosed within 60 days following COVID-19 vaccination; 76% of cases (79/104) were confirmed as postvaccination postmenopausal bleeding after chart review. Median time from vaccination to bleeding onset was 21 days (range: 2-54 days). Among the 56 postmenopausal bleeding cases with a provider-attributed etiology, the common causes of bleeding were uterine or cervical lesions (50% [28/56]), hormone replacement therapy (13% [7/56]), and proliferative endometrium (13% [7/56]). Among the 23 cases without a clear etiology, there was no statistically significant clustering of postmenopausal bleeding onset following vaccination. CONCLUSION: Within this integrated health system, introduction of COVID-19 vaccines was not associated with an increase in incident postmenopausal bleeding diagnoses. Diagnosis of postmenopausal bleeding in the 60 days following receipt of a COVID-19 vaccination was rare.
引用
- Kauffman TL, Irving SA, Brooks N, et al. Postmenopausal bleeding after COVID-19 vaccination. Am J Obstet Gynecol. 2023. PMID: 37726057. doi:10.1016/j.ajog.2023.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。